1471
A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy
Condition(s):Hematological Malignancy; Leukemia; Lymphoma; Multiple MyelomaLast Updated:January 22, 2020Completed
Refractory Multiple Myeloma: 1500 Clinical Trials, Page 148 of 150
Hide Studies Not Open or Pending
1472
Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)
Condition(s):Acute Lymphoblastic LeukemiaLast Updated:February 19, 2020Completed
1473
Natural Killer Cells and Bortezomib to Treat Cancer
Condition(s):Chronic Myeloid Leukemia (CML); Pancreatic Ca; Colon/Rectal Ca; Multiple Myeloma; Carcinoma, Non-Small -Cell LungLast Updated:September 26, 2023Completed
1474
Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy
Condition(s):Acute Myeloid Leukemia; Acute Lymphocytic Leukemia; Chronic Lymphocytic Leukemia; Myelodysplasia; Lymphoma, Non-Hodgkin; Hodgkin’s Lymphoma; Multiple MyelomaLast Updated:June 22, 2015Terminated
1475
Phase II Trial of Tirelizumab Combined With R2-ICE Regimen in the Treatment of rrDLBCL/HGBL
Condition(s):Age Range ≥16 Years, Gender Unlimited; Histopathology Confirmed Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma; Received Prior First-line Chemotherapy for DLBCL or HGBL, Failed to Reach CR for Four Cycles, or Relapsed; At Least One Positive Lesion According to the 2014 Lugano Criteria for Hodgkin’s and Non-Hodgkin’s Lymphoma; ECOG Physical Status Score is 0-3; The Researchers Judged That Life Expectancy Was at Least Three Months; Understand and Voluntarily Sign Written Informed ConsentLast Updated:September 20, 2021Unknown status
1476
A Phase I Trial of ZIO-101 in Hematologic Cancers
Condition(s):Acute Leukemia; Chronic Myeloproliferative Disease; Chronic Lymphoproliferative Disease; Multiple Myeloma; Lymphoma; Poor-risk Myelodysplasia (MDS)Last Updated:July 19, 2012Completed
1477
Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients
Condition(s):Multiple MyelomaLast Updated:October 25, 2021Recruiting
1478
Prognostic Value of Clinical and Biological Factors in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma
Condition(s):Diffuse Large B-cell LymphomaLast Updated:April 18, 2016Completed
1479
Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer
Condition(s):Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Refractory Chronic Lymphocytic Leukemia; Multiple MyelomaLast Updated:January 4, 2019Completed
1480
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Condition(s):Non Hodgkin Lymphoma; Richter Transformation; Multiple Myeloma; T-cell-prolymphocytic Leukemia; Acute Myeloid Leukemia; Acute Lymphocytic Leukemia; Myeodysplastic Syndrome; Myelodysplastic/Myeloproliferative Neoplasm; Myelofibrosis; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Chronic Myelomonocytic Leukemia-2; Myelodysplastic Neoplasm in Blast PhaseLast Updated:March 29, 2023Recruiting